Revenue Update on Sangamo Biosciences(NASDAQ:SGMO)

Sangamo Biosciences(NASDAQ:SGMO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $3.70M. Analysts estimated a revenue of $5.38M. Earnings per share were $-0.38. Analysts had estimated an EPS of $-0.24.

Sangamo Biosciences (SGMO) shares turned negative on Fridays trading session with the shares closing down -0.03 points or -0.68% at a volume of 14,19,378. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.52. The peak price level was also seen at $4.52 while the days lowest was $4.36. Finally the shares closed at $4.41. The 52-week high of the shares is $9.91 while the 52-week low is $4.36. According to the latest information available, the market cap of the company is $311 M.

Several Insider Transactions has been reported to the SEC. On Jul 17, 2015, Edward O Ii Lanphier (President & CEO) sold 25,000 shares at $10.43 per share price.Also, On Jul 14, 2015, Henry Ward Wolff (Exec VP & CFO) sold 12,000 shares at $10.00 per share price.On Jun 9, 2015, Dale G Ando (VP, Therapeutic Dev. & CMO) sold 15,000 shares at $12.29 per share price, according to the Form-4 filing with the securities and exchange commission.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company’s lead ZFP Therapeutic SB-728-T a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company’s clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimer’s disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Sangamo Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sangamo Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.